P
Peter R. Allegrini
Researcher at Novartis
Publications - 71
Citations - 7161
Peter R. Allegrini is an academic researcher from Novartis. The author has contributed to research in topics: Ischemia & In vivo. The author has an hindex of 36, co-authored 71 publications receiving 6913 citations. Previous affiliations of Peter R. Allegrini include Ciba Specialty Chemicals & Max Planck Society.
Papers
More filters
Journal ArticleDOI
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Sung Hee Um,Francesca Frigerio,Mitsuhiro Watanabe,Frédéric Picard,Manel Joaquin,Melanie Sticker,Stefano Fumagalli,Peter R. Allegrini,Sara C. Kozma,Sara C. Kozma,Johan Auwerx,George Thomas +11 more
TL;DR: It is reported that S6K1-deficient mice are protected against obesity owing to enhanced β-oxidation, however on a high fat diet, levels of glucose and free fatty acids still rise in S6k1- deficient mice, resulting in insulin receptor desensitization.
Journal Article
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. [Erratum: 2004 Sept. 23, v. 431, no. 7007, p. 485.]
Sung Hee Um,Francesca Frigerio,Mitsuhiro Watanabe,Frédéric Picard,Manel Joaquin,Melanie Sticker,Stefano Fumagalli,Peter R. Allegrini,Sara C. Kozma,Johan Auwerx +9 more
TL;DR: In this article, S6K1-deficient mice are protected against obesity owing to enhanced β-oxidation, but on a high fat diet, levels of glucose and free fatty acids still rise in S6k1-dependent mice, resulting in insulin receptor desensitization.
Journal ArticleDOI
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Peter Traxler,Peter R. Allegrini,Ralf Brandt,Josef Brueggen,Robert Cozens,Doriano Fabbro,Konstantina Grosios,Heidi Lane,Paul M.J. McSheehy,Juergen Mestan,Thomas J. Meyer,Careen Tang,Markus Wartmann,Jeanette Marjorie Wood,Giorgio Caravatti +14 more
TL;DR: Data indicate that AEE788 has potential as an anticancer agent targeting deregulated tumor cell proliferation as well as angiogenic parameters, and is currently in Phase I clinical trials in oncology.
Journal ArticleDOI
Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model
TL;DR: The results of this study indicate that inhibition of MCP-1 signaling could be a new acute treatment approach to limit infarct size after stroke.
Journal ArticleDOI
Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct.
TL;DR: The spatial and temporal correlation between the induction of angiogenesis with V EGF and VEGFR-1 expression suggests that the ischemic upregulation of VEGF represents a physiological response of the brain to counterbalance hypoxia/ischemia in order to protect neuroectodermal tissue.